Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 


Proteon Therapeutics, Inc.

Statements of Cash Flows

(in thousands)

 
  Year Ended
December 31,
  Six Months
Ended June 30,
 
 
  2012   2013   2013   2014  
 
   
   
  (unaudited)
 

Operating activities:

                         

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )

Reconciliation of net loss to net cash used in operating activities:

                         

Depreciation

    57     27     15     13  

Amortization of premium/discount on available-for-sale securities

    138     30     20     6  

Gain on sale of fixed assets

    (5 )   (65 )   (4 )    

Accretion of discount & debt issuance cost of convertible notes payable

        749         742  

Stock-based compensation

    110     155     105     49  

Change in fair value of investor rights/obligations

                18  

Change in fair value of derivative liability

        (2 )       81  

Changes in:

                         

Prepaid expenses and other assets

    320     71     97     (1,480 )

Interest receivable

    28     1     8     (1 )

Accounts payable and accrued expenses

    (912 )   177     (215 )   1,617  

Accrued interest payable

        112         115  
                   

Net cash used in operating activities

    (8,234 )   (6,657 )   (3,386 )   (4,234 )

Investing activities:

                         

Purchases of available-for-sale investments

    (8,658 )   (3,878 )   (1,510 )   (16,795 )

Proceeds from maturities of available for sale investments

    16,075     6,550     5,800     2,355  

Purchase of property and equipment

    (67 )   (10 )       (36 )

Sale of property and equipment

    33     65     4      

Deposits

    (1 )            
                   

Net cash provided by investing activities

    7,382     2,727     4,294     (14,476 )

Financing activities:

                         

Proceeds from issuance of Series D preferred stock

                25,000  

Issuance costs for preferred stock

                (437 )

Proceeds from issuance of convertible notes payable

        4,339          

Payments for debt issuance costs

        (46 )        

Exercise of stock options

        19         0  

Early exercise of stock options

          2          

Repayments of note payable

    (9 )            
                   

Net cash (used in) provided by financing activities

    (9 )   4,314         24,563  
                   

(Decrease) increase in cash and cash equivalents

    (861 )   384     908     5,853  
                   

Cash and cash equivalents, beginning of period

    3,270     2,409     2,409     2,793  
                   

Cash and cash equivalents, end of period

  $ 2,409   $ 2,793   $ 3,317   $ 8,646  
                   
                   

Supplemental disclosure of non-cash investing and financing activities:

                         

Accretion of redeemable convertible preferred stock to redemption value

  $ 6,133   $ 6,119   $ 1,515   $ 3,409  
                   
                   

Fair value of embedded derivative contained within convertible notes payable

  $   $ 1,445   $   $  
                   
                   

   

See accompanying notes to financial statements.

F-6